Liraglutide

Limits on what this shows

• Key negative/null findings: No study located reported liraglutide worsening or having no effect on mitochondrial structure/function; all located studies report a protective or neutral-to-protective direction. This absence of a contrary finding should be read as a gap in adversarial testing, not proof of universal benefit.
• At-risk subgroups: Not applicable; findings are protective in direction.
• Counter-evidence on record: All evidence is preclinical (cell lines or animal models); no human systemic mitochondrial-function outcome study was located.

Regulatory status

Not addressed in the FDA label.

Population evidence

In vitro, human-derived cells: liraglutide "demonstrates a therapeutic effect on mitochondrial dysfunction in human SGBS adipocytes" (Diabetes Res Clin Pract 2023, PMID 36958431); liraglutide "prevents high glucose induced HUVECs dysfunction via inhibition of PINK1/Parkin-dependent mitophagy" in human umbilical vein endothelial cells (Mol Cell Endocrinol 2022, PMID 35032624). Animal: liraglutide "protects cardiomyocytes from IL-1beta-induced metabolic disturbance and mitochondrial dysfunction" (Chem Biol Interact 2020, PMID 32898504); liraglutide "provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts" (J Physiol Biochem 2023, PMID 36515811).

Mechanism

Named across sources: GLP-1 receptor-mediated PI3K/Akt signaling, PINK1/Parkin mitophagy regulation, and (per the bone systematic review below) AMPK/PGC1α pathway activation.

Counter-evidence held on record

This is not a depletion signal. It should never be reworded as "liraglutide harms mitochondria." It should also not be used to justify mitochondrial-support supplements, since the evidence suggests no deficit to correct.

Limits on what this shows

• Key negative/null findings: None located showing liraglutide increasing oxidative stress; one source (Gac Med Mex 2025) used liraglutide in combination with empagliflozin, which limits attribution to liraglutide alone and is noted as a counter-evidence limitation.
• At-risk subgroups: Not applicable; findings are protective in direction.
• Counter-evidence on record: All evidence located is preclinical (cell or animal models); no human systemic oxidative-stress-marker RCT for liraglutide was retrieved before this review's search tools were rate-limited.

Regulatory status

Not addressed in the FDA label.

Population evidence

In vitro, human-derived cells: liraglutide "reduces oxidative stress and improves energy metabolism in methylglyoxal-induced SH-SY5Y cells" (Neurotoxicology 2022, PMID 35985417); liraglutide "ameliorates lipotoxicity-induced oxidative stress by activating the NRF2 pathway in HepG2 cells" (Horm Metab Res 2020, PMID 32375182). Animal: liraglutide reduces oxidative stress in hyperglycemic H9c2 cardiomyocytes (Medicina 2025, PMID 41155741); suppresses oxidative stress in diabetic corneal nerve regeneration via PI3K/AKT (Eur J Pharmacol 2025, PMID 41109401); with empagliflozin, reduces oxidative stress/inflammation in diabetic cardiomyopathy (Gac Med Mex 2025, PMID 41061250, combination therapy — not isolated to liraglutide alone); inhibits oxidative stress/neuroinflammation via Nrf2/HO-1 and MAPK/NF-kB pathways in a cognitive-deficit model (Int Immunopharmacol 2024, PMID 39321702). A systematic review of 17 preclinical liraglutide-and-bone studies additionally reports liraglutide "increases SOD, CAT; reduces ROS/MDA" as one of five identified protective pathways (Frontiers in Endocrinology 2024, DOI 10.3389/fendo.2024.1378291).

Mechanism

Named: NRF2/HO-1 pathway activation, PI3K/AKT signaling, and direct reduction of reactive oxygen species and malondialdehyde with increased superoxide dismutase/catalase activity.

Counter-evidence held on record

This is a reverse-direction (protective) finding, not a depletion signal, and is capped at yellow because it is preclinical only. It should not be used to justify antioxidant supplementation, which the evidence does not support as necessary.

Limits on what this shows

• Key negative/null findings: Direct PubMed queries for "liraglutide iron ferritin" and "liraglutide hemoglobin hematocrit" returned no liraglutide-specific hits; "liraglutide copper" returned only unrelated copper-64 PET radiotracer studies, not nutrient-status data.
• At-risk subgroups: Menstruating women, patients with reduced meat/iron-rich food intake from early satiety.
• Counter-evidence on record: The comparator design (GLP-1 RA users vs. SGLT2-inhibitor users) is an active-comparator study, which per Step 5 does not establish an effect versus no treatment; SGLT2 inhibitors have their own, separately documented effects on iron indices, which limits interpretation of the "26-30% lower" figure as a pure liraglutide/GLP-1 effect.

Regulatory status

Not listed as a nutrient interaction in the FDA label.

Population evidence

Narrative review (Tier C, class-level): "Iron depletion occurred frequently, with users showing 26%-30% lower ferritin levels than SGLT2 inhibitor comparators," and "over 60% consumed insufficient... iron" (Urbina et al., Clinical Obesity 2026, n=480,825).

Mechanism

Present (mechanism H, reduced intake). No chelation or absorption-blocking mechanism for iron specifically was identified in the label or in any liraglutide-specific study.

Counter-evidence held on record

The comparator study design limits causal attribution; this is a class-level, intake-driven signal, not a confirmed liraglutide-specific iron-wasting mechanism. No iron dose is recommended without testing.

Limits on what this shows

• Why no grade: Dual condition met: (1) No Tier B or Tier C evidence exists — a PubMed search for "liraglutide copper" returned only unrelated copper-64 radiotracer imaging studies ([Cu-64]DOTATATE PET/CT used to image vascular/coronary inflammation, PMID 34441365 and 34917038), not nutrient-status data. (2) No circulating consumer claim naming copper specifically was found; the class-level narrative review (Urbina et al. 2026) names vitamin D, calcium, iron, thiamine, and cobalamin, but not copper.

Tooling note

Europe PMC and Semantic Scholar queries for liraglutide+copper were also attempted but repeatedly rate-limited (HTTP 429) during this session; the PubMed search that did complete returned a genuine, on-topic zero/near-zero result, giving reasonable confidence this reflects an actual evidence gap rather than only a blocked search.

Limits on what this shows

• Key negative/null findings: No study located reported a harmful dysbiosis signature, reduced diversity, or a clinical dysbiosis-linked adverse outcome (e.g., C. difficile risk) attributable to liraglutide specifically.
• At-risk subgroups: None identified; existing data are predominantly in T2DM populations.
• Counter-evidence on record: These are comparator or single-arm mechanistic studies, not placebo-controlled dysbiosis-outcome trials; "risk" in the category name is not established for liraglutide, only compositional change.

Regulatory status

Not addressed in the FDA label.

Population evidence

Human, liraglutide-specific: a 12-week trial in T2DM/NAFLD patients found liraglutide "significantly increased the diversity and richness of the intestinal bacterial community" versus metformin (Front Microbiol 2023, PMID 36778868); a trial in elderly T2D patients on insulin degludec/liraglutide found glycemic responders had "a significant increase in Gram-negative Alistipes," correlated with cognitive improvement (Aging Dis 2023, PMID 37008061); a trial comparing metformin- and liraglutide-treated T2DM subjects confirmed both drugs modify the GI microbiome (Endocrinol Diabetes Metab 2017/2018, PMID 30815546); a youth-onset T2D trial found metformin+liraglutide shifted bile-acid-linked taxa correlating with improved fasting glucose (Gut Microbes 2025, PMID 41020378). A systematic review of 38 studies concluded "liraglutide promotes the growth of beneficial genera relevant for beneficial metabolic functions" (Nutrients 2025, PMID 40284168). Animal studies (db/db mice, diabetic rats) consistently report increases in Akkermansia, Bifidobacterium, Lactobacillus and normalization of the Firmicutes/Bacteroidetes ratio (Life Sci 2020 PMID 32961235; Eur J Pharmacol 2024 PMID 39154828; Biomed Pharmacother 2026 PMID 41633255).

Mechanism

Present (mechanism G): altered gut motility/transit from delayed gastric emptying, plus GLP-1-receptor-mediated changes in bile-acid signaling, are named across these sources as plausible drivers of compositional change.

Counter-evidence held on record

This is not a depletion or harm signal. The evidence base, including multiple liraglutide-specific human trials, trends toward a favorable compositional shift. It should not be marketed as a "microbiome risk" to consumers; it is disclosed here because the category is evaluated on every drug regardless of direction.

Limits on what this shows

• Key negative/null findings: None located showing reduced ATP output or worsened energy metabolism with liraglutide; the Warburg-reversal finding in cancer cells is a distinct, cancer-specific metabolic context and should not be generalized to normal tissue energy status.
• At-risk subgroups: Not applicable; findings are protective in direction.
• Counter-evidence on record: All evidence located is preclinical (cell or animal models); no human systemic ATP/energy-metabolism outcome study for liraglutide was retrieved.

Regulatory status

Not addressed in the FDA label.

Population evidence

"A Pharmacological Dose of Liraglutide Improves Mitochondrial Performance in Mouse Leydig Cells" (Int J Mol Sci 2025, PMID 41009468); liraglutide "attenuates clozapine-induced mitochondrial dysfunction and improves energy metabolism in the brain of rats" (Biochem Pharmacol 2025, PMID 40588078); liraglutide "repairs the infarcted heart" via the "SIRT1/Parkin/mitophagy pathway" (Mol Med Rep 2018, PMID 29328405); GLP-1 analogues including liraglutide "activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells" (Med Oncol 2024, PMID 38705935, in vitro human cell line).

Mechanism

Named: AMPK activation, SIRT1/Parkin-mediated mitophagy supporting mitochondrial quality control, and (shared with the Mitochondrial burden entry) AMPK/PGC1α pathway activation reported in the liraglutide-bone systematic review.

Counter-evidence held on record

This directly contradicts, rather than supports, consumer claims that liraglutide "drains your energy at the cellular level." It is a reverse-direction finding capped at yellow because it is preclinical only, and should not be used to market energy-support supplements alongside liraglutide.

Limits on what this shows

• Why no grade: Dual condition met: (1) No Tier B or C evidence exists — "liraglutide hemoglobin hematocrit" returned zero PubMed results, and a broader "liraglutide tissue oxygenation" search (43 results) surfaced only tissue-level metabolic/mitochondrial studies (adipose thermogenesis, cardiac, pulmonary, ocular), none addressing systemic oxygen-carrying capacity or red-cell parameters. The FDA label's pharmacokinetic section contains no mechanism (e.g., diuretic-driven hemoconcentration, as seen with SGLT2 inhibitors) that would plausibly alter hematocrit. (2) No circulating consumer claim specifically tying liraglutide to oxygen delivery or "low energy via poor oxygenation" was located.

Tooling note

An additional confirmatory "liraglutide anemia" PubMed query was attempted but blocked by rate-limiting before completion; given the consistent negative results from the two queries that did complete, across two different phrasings, this is recorded as a genuine gap rather than a pure tooling failure, with the caveat noted for a future revision.